Clene Inc. (CLNN) is a clinical-stage biopharmaceutical company focused on developing new therapeutic strategies for treating neurological disorders, such as multiple sclerosis (MS), Parkinson's disease, and amyotrophic lateral sclerosis (ALS). It is a pioneer in the field, developing novel therapeutics by harnessing the power of nanotechnology to create a new class of drugs called nanocatalysts.
Clene Inc. was founded in 2013 and is based in Salt Lake City, USA. It envisions to evolve standard of care in neurodegenerative diseases by providing disease-modifying therapies that show superior efficacy, safety, and tolerability profiles. The company uses nanoparticle technology to design treatments that target the underlying causes of neurodegeneration, targeting reactive oxygen species (ROS) to restore cellular health.
Clene's key product candidate is a proprietary nanocatalytic molecule known as CNM-Au8. It is gold nanoparticles formulated to utilize bioenergetic catalysis to support cellular health. CNM-Au8 is currently undergoing clinical trials for multiple sclerosis, Parkinson's disease, and ALS. The initial trials have shown promise, and the product received "Fast Track" designation from the U.S. Food and Drug Administration (FDA) for the treatment of Amyotrophic Lateral Sclerosis (ALS).
Clene Inc. also explores the potential of other nanocatalysts by having a rich pipeline of clinical and pre-clinical programs. Its novel approach to treating neurodegenerative diseases has attracted significant interest and investment. Following the completion of a merger with Tottenham Acquisition I Limited in December 2020, the company was listed on the Nasdaq Global Market under the ticker symbol "CLNN".
The leadership team at Clene Inc. is a robust combination of scientific experts, leaders with extensive biopharma execution expertise, and experienced industry veterans. Together, they are dedicated to changing the lives of individuals affected by neurodegenerative diseases and committed to the science behind their innovative approach.
Despite being a relatively young company, Clene Inc. has shown enormous potential through its innovative approach to treating significant and unmet medical needs. By focusing on developing new therapies for neurologic diseases, the company has positioned itself as an exciting player in the pharmaceuticals and biotechnology industry. However, as with any company in the clinical-stage, the risks and uncertainties inherent in drug development and regulatory approval processes should not be overlooked. If successful, Clene Inc. could potentially revolutionize treatment for millions of people living with debilitating neurodegenerative diseases worldwide.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Clene Inc. has closed a $4 million registered direct offering, with investments led by its Chairman, founding investor Kensington Capital Holdings, and the CEO. This funding is expected to extend the company's capital runway until mid-first quarter 2027, which is beyond the potential FDA decision on its CNM-Au8® NDA for ALS. Additionally, if the NDA is accepted, Clene could receive an extra $6.7 million to $7.8 million from warrants, further bolstering its cash position.
Clene Inc. (Nasdaq: CLNN), a clinical-stage biotechnology company, announced a $4 million registered direct offering of 1,219,513 shares at $3.28 per share to existing shareholders, including insiders. The offering, led by Clene's Chairman and founding investor Kensington Capital Holdings, is expected to close on September 17, 2026. The proceeds are intended to fund the company's operations until mid-first quarter 2027 and support regulatory efforts for its drug candidate CNM-Au8.
Clene Inc. (Nasdaq: CLNN) announced its management will present at two September investor conferences: the 2026 Cantor Global Healthcare Conference on September 9th and the H.C. Wainwright 28th Annual Global Investment Conference on September 15th. The company will also host one-on-one investor meetings at both events, with webcasts available for the presentations. Clene is a late clinical-stage biopharmaceutical company focusing on neurodegenerative diseases.
Clene Inc. (Nasdaq: CLNN) announced that its management will present a corporate update at the Emerging Growth Conference on August 19, 2026, at 3:10 p.m. ET. The presentation will be available via webcast on the "Events" section of Clene's website. Clene is a late clinical-stage biopharmaceutical company focused on neurodegenerative diseases, developing CNM-Au8® to improve mitochondrial health and neuronal function.